{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:32:30Z","timestamp":1787729550955,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcpo.2026.100717","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:19:57Z","timestamp":1771258797000},"page":"100717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Speed and nature of national comprehensive cancer network updates following food and drug administration approvals & withdrawals"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5798-6742","authenticated-orcid":false,"given":"Christopher L.","family":"Rios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jcpo.2026.100717_bib1","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41571-024-00948-1","article-title":"The high costs of anticancer therapies in the USA: challenges, opportunities and progress","volume":"21","author":"Jazowski","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.jcpo.2026.100717_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.4115","article-title":"Reforming Reimbursement for the US Food and Drug Administration\u2019s Accelerated Approval Program to Support State Medicaid Programs","volume":"3","author":"Sachs","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"15","key":"10.1016\/j.jcpo.2026.100717_bib3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.2016.12770","article-title":"Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology","volume":"316","author":"Green","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jcpo.2026.100717_bib4","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2008.0049","article-title":"Medicare Recognizes NCCN Compendium","volume":"6","author":"McGivney","year":"2008","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.jcpo.2026.100717_bib5","doi-asserted-by":"crossref","first-page":"k668","DOI":"10.1136\/bmj.k668","article-title":"Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study","volume":"360","author":"Wagner","year":"2018","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.jcpo.2026.100717_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.43285","article-title":"National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval","volume":"6","author":"Cliff","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2026.100717_bib7","doi-asserted-by":"crossref","first-page":"n1959","DOI":"10.1136\/bmj.n1959","article-title":"Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study","volume":"374","author":"Gyawali","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcpo.2026.100717_bib8","unstructured":"Research C for DE and. Oncology (Cancer)\/Hematologic Malignancies Approval Notifications. FDA [Internet]. 2024 Nov 21 [cited 2024 Dec 4]; Available from: \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/oncology-cancerhematologic-malignancies-approval-notifications\u3009."},{"key":"10.1016\/j.jcpo.2026.100717_bib9","unstructured":"Research C for DE and. Withdrawn | Cancer Accelerated Approvals. FDA [Internet]. 2024 Dec 3 [cited 2024 Dec 8]; Available from: \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/withdrawn-cancer-accelerated-approvals\u3009."},{"key":"10.1016\/j.jcpo.2026.100717_bib10","unstructured":"Federal Register [Internet]. [cited 2024 Dec 8]. Federal Register Documents Currently on Public Inspection. Available from: \u3008https:\/\/www.federalregister.gov\/public-inspection\/current\u3009."},{"issue":"15_","key":"10.1016\/j.jcpo.2026.100717_bib11","article-title":"A review of evidence supporting NCCN category 2B off-label recommendations for determination of Medicare reimbursement eligibility","volume":"39","author":"DiScala","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jcpo.2026.100717_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7190","article-title":"An empirical analysis of overall survival in drug approvals by the US FDA (2006\u20132023)","volume":"13","author":"Elbaz","year":"2024","journal-title":"Cancer Med"},{"issue":"16","key":"10.1016\/j.jcpo.2026.100717_bib13","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jcpo.2026.100717_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"22","key":"10.1016\/j.jcpo.2026.100717_bib15","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1182\/bloodadvances.2023010298","article-title":"Phase 3 SELENE study: ibrutinib plus BR\/R-CHOP in previously treated patients with follicular or marginal zone lymphoma","volume":"7","author":"Nastoupil","year":"2023","journal-title":"Blood Adv."},{"issue":"26","key":"10.1016\/j.jcpo.2026.100717_bib16","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.jcpo.2026.100717_bib17","doi-asserted-by":"crossref","unstructured":"Lipfert C., Kim M.S., Haslam A., Prasad V.K. Recall of ibrutinib and issues with therapeutic approval. BMJ Oncol [Internet]. 2024 Aug 7 [cited 2024 Sept 30];3(1). Available from: \u3008https:\/\/bmjoncology.bmj.com\/content\/3\/1\/e000418\u3009.","DOI":"10.1136\/bmjonc-2024-000418"},{"issue":"2","key":"10.1016\/j.jcpo.2026.100717_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.healthpol.2014.11.012","article-title":"Medicare\u2019s use of cost-effectiveness analysis for prevention (but not for treatment)","volume":"119","author":"Chambers","year":"2015","journal-title":"Health Policy"},{"key":"10.1016\/j.jcpo.2026.100717_bib19","unstructured":"NCCN [Internet]. [cited 2026 Jan 7]. Guidelines With Evidence Blocks. Available from: \u3008https:\/\/www.nccn.org\/guidelines\/guidelines-with-evidence-blocks\u3009."},{"issue":"7","key":"10.1016\/j.jcpo.2026.100717_bib20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40273-020-00901-x","article-title":"The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating","volume":"38","author":"Mitchell","year":"2020","journal-title":"PharmacoEconomics"},{"issue":"4","key":"10.1016\/j.jcpo.2026.100717_bib21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/jamaoncol.2022.7770","article-title":"Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval","volume":"9","author":"Parikh","year":"2023","journal-title":"JAMA Oncol."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:30:32Z","timestamp":1777627832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538326000172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"alternative-id":["S2213538326000172"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100717","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Speed and nature of national comprehensive cancer network updates following food and drug administration approvals & withdrawals","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100717"}}